Disease severity and costs among patients starting a treatment with COX-2 specific inhibitors versus NSAIDs patients in Italy: Quantitative assessment in 442 patients with arthritis

被引：0
|
作者：
Lucioni, C
Chinellato, A
Mazzi, S
Roggeri, D
Chiroli, S
机构：
[1] Adis Int Ltd, Milan, Italy
[2] Serv Farmaceut Terr, Treviso, Italy
[3] Pharmacia Italia SpA, Milan, Italy
来源：
VALUE IN HEALTH | 2002年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61270-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：476 / 477
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
    Yun, HR
    Bae, SC
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (01) : 9 - 14
  • [22] Use of COX-2 inhibitors in patients with retinal venous occlusive disease
    Recchia, Franco M.
    Chen, Eric
    Li, Chun
    Maguluri, Srilakshmi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (01): : 134 - 137
  • [23] Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
    Hyung Ran Yun
    Sang-Cheol Bae
    Rheumatology International, 2005, 25 : 9 - 14
  • [24] Cox-2 inhibitors in the treatment of small cell lung cancer patients
    Boutsikou, Efimia
    Zarogoulidis, Paul
    Konstanta, Tania
    Lampaki, Sofia
    Vlogiaris, Lefteris
    Spyratos, Dionisis
    Zarogoulidis, Konstantinos
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [25] COX-2 selective inhibitors - they are still the best treatment for many patients!
    Brune, K
    SWISS MEDICAL WEEKLY, 2005, 135 (11-12) : 163 - 165
  • [26] The role of COX-2 selective inhibitors in the treatment of patients with breast cancer
    Kolyadina, I. V.
    Poddubnaya, I. V.
    Komov, D. V.
    Rostchin, E. M.
    Ozhereliev, A. S.
    Orinovsky, M. B.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2011, (01) : 108 - 111
  • [27] Costs and health consequences of replacing NSAIDs by selective cox-2-inhibitors in patients at risk of cardiovascular disease.
    Linnestad, K
    Kristiansen, IS
    Kvien, TK
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S386 - S386
  • [28] Efficacy and safety of celecoxib, a specific COX-2 inhibitor in patients with rheumatoid arthritis
    Geis, GS
    Hubbard, RC
    Callison, DA
    Yu, S
    Zhao, W
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S70 - S70
  • [29] Hypertensive effects of COX-2 specific inhibitors in elderly osteoarthritis patients.
    Whelton, A
    Bello, A
    Fort, J
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S6 - S7
  • [30] Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs - Why were patients at major risk excluded?
    Puccetti, L
    BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7530): : 1474 - 1474
12345